VasoDynamics files global patent (PCT) for the methods to select patients for the clinical studies on radiation-induced oral mucositis

Platform products Intellectual Property protection extended to 2043

10th October 2023 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, today announces that it has filed a global Patent Co-Operation Treaty (PCT) for the method of using radiotherapy parameters for clinical studies on radiation induced oral mucositis, supported by leading IP agency Gill Jennings & Every LLP. This patent specified the methodology of selecting the patients with high risk of developing severe mucositis induced by radiation exposure.

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“The patent demonstrates the Company’s in-depth expertise in radiotherapy related clinical trial design and management, an ethical mindset of minimising patient risk by increasing the relevance and accuracy of patient selection. This also represents an important element of our IP strategy as we progress a number of programmes aimed at transforming the standard of supportive care for a broad range of cancer patients worldwide.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating, and often dose-limitin,g complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve selective protection of normal tissue during cancer treatment whilst facilitating anti-cancer therapy efficacy.